DCF Advisers LLC Takes $1.42 Million Position in Immuneering Corporation $IMRX

DCF Advisers LLC purchased a new stake in shares of Immuneering Corporation (NASDAQ:IMRX) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 215,000 shares of the company’s stock, valued at approximately $1,415,000. DCF Advisers LLC owned about 0.33% of Immuneering as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Jane Street Group LLC bought a new position in Immuneering in the 1st quarter valued at approximately $32,000. Geode Capital Management LLC lifted its position in Immuneering by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock valued at $776,000 after acquiring an additional 4,458 shares in the last quarter. XTX Topco Ltd bought a new stake in Immuneering in the 2nd quarter worth about $90,000. Bridgeway Capital Management LLC raised its position in Immuneering by 57.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company’s stock worth $322,000 after buying an additional 35,000 shares during the last quarter. Finally, Corient Private Wealth LLC purchased a new position in Immuneering in the 2nd quarter worth about $215,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Immuneering Trading Down 2.7%

Shares of NASDAQ:IMRX opened at $3.92 on Thursday. The stock has a 50 day moving average of $5.21 and a 200 day moving average of $5.46. The company has a market cap of $253.62 million, a PE ratio of -3.35 and a beta of 0.38. Immuneering Corporation has a 12-month low of $1.66 and a 12-month high of $10.08.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.09. Equities research analysts predict that Immuneering Corporation will post -1.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on IMRX shares. Chardan Capital reissued a “buy” rating and issued a $20.00 target price on shares of Immuneering in a research report on Tuesday, May 19th. Wall Street Zen raised Immuneering from a “sell” rating to a “hold” rating in a research report on Sunday, April 19th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of Immuneering in a research report on Monday, March 9th. Oppenheimer reissued an “outperform” rating on shares of Immuneering in a research report on Monday, June 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a research note on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Immuneering currently has an average rating of “Moderate Buy” and an average price target of $16.50.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.